{"id":"W4310718486","doi":"10.1016/s2468-1253(22)00389-2","title":"Neutralising antibody potency against SARS-CoV-2 wild-type and omicron BA.1 and BA.4/5 variants in patients with inflammatory bowel disease treated with infliximab and vedolizumab after three doses of COVID-19 vaccine (CLARITY IBD): an analysis of a prospective multicentre cohort study","year":2022,"lang":"en","type":"article","venue":"˜The œLancet. Gastroenterology & hepatology","topic":"SARS-CoV-2 and COVID-19 Research","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Allergan; Sanofi Pasteur; Seqirus; Crohn's and Colitis UK; National Institute for Health and Care Research; Celltrion; Mylan; Bristol-Myers Squibb; Eli Lilly and Company; UK Research and Innovation; AstraZeneca; Celltrion Healthcare; Medical Research Council; Chan Zuckerberg Initiative; Celgene; Biogen; University of Ottawa; Sanofi; NIHR Imperial Biomedical Research Centre; Amgen; Vifor Pharma; Pfizer","keywords":"Infliximab; Medicine; Vedolizumab; Antibody; Virology; Vaccination; Immunology; Inflammatory bowel disease; Drug; Disease; Tumor necrosis factor alpha; Pharmacology; Internal medicine","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001582068,0.0006488805,0.0009518036,0.0006157875,0.0005647094,0.0009758217,0.0007727819,0.001082974,0.001328886],"category_scores_gemma":[0.002970843,0.0006793549,0.001340737,0.0008390705,0.0004713628,0.0007350041,0.0006770507,0.000969799,0.0003331107],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005311962,"about_ca_system_score_gemma":0.0002964083,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002652431,"about_ca_topic_score_gemma":0.002351773,"domain_scores_codex":[0.9987663,0.0003506031,0.0001482507,0.0003891524,0.0001671896,0.0001786126],"domain_scores_gemma":[0.9973672,0.0003409907,0.001229606,0.0003463248,0.0001880386,0.0005278533],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.002733073,0.000122945,0.9947935,0.0000207909,0.0003003128,0.000108067,0.0001352793,0.00004310991,0.0009430666,0.00001082043,0.00008297125,0.000706076],"study_design_scores_gemma":[0.0000985305,0.0009038654,0.9983925,0.000003712411,0.00009416904,0.0001949801,0.00007036616,0.00008239169,0.00006160626,0.000005191868,0.00008746994,0.000005097872],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9995395,0.0001407594,0.00003062123,0.000009561508,0.000004224184,0.00001613041,0.0001810545,0.000001379825,0.00007691139],"genre_scores_gemma":[0.9995359,0.00003584549,0.00003763819,0.00002012118,0.000008127295,0.00001466049,0.0002871305,0.000001168353,0.00005928755],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002652431,"threshold_uncertainty_score":0.008366883,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01462298993683157,"score_gpt":0.2969978580531352,"score_spread":0.2823748681163036,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}